Accepted Manuscript

Title: Timing and Causes of Readmission after Acute Heart Failure Hospitalization – Insights from the Heart Failure Network Trials

Author: Justin M. Vader, Shane J. LaRue, Susanna R. Stevens, Robert J. Mentz, Adam D. DeVore, Anuradha Lala, John D. Groarke, Omar F. AbouEzzeddine, Shannon M. Dunlay, Justin L. Grodin, Victor G. Dávila-Román, Lisa de las Fuentes


PII: S1071-9164(16)30059-8

DOI: http://dx.doi.org/doi: 10.1016/j.cardfail.2016.04.014

Reference: YJCAF 3760

To appear in: Journal of Cardiac Failure

Received date: 28-10-2015 Revised date: 25-4-2016 Accepted date: 26-4-2016



Please cite this article as: Justin M. Vader, Shane J. LaRue, Susanna R. Stevens, Robert J. Mentz, Adam D. DeVore, Anuradha Lala, John D. Groarke, Omar F. AbouEzzeddine, Shannon M. Dunlay, Justin L. Grodin, Victor G. Dávila-Román, Lisa de las Fuentes, Timing and Causes of Readmission after Acute Heart Failure Hospitalization – Insights from the Heart Failure Network Trials, *Journal of Cardiac Failure* (2016), http://dx.doi.org/doi: 10.1016/j.cardfail.2016.04.014.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Timing and Causes of Readmission after Acute Heart Failure Hospitalization - Insights from the Heart Failure Network Trials

Authors: Justin M. Vader MD, MPHS¹; Shane J. LaRue MD, MPHS¹; Susanna R. Stevens, MS²; Robert J. Mentz, MD²; Adam D. DeVore, MD²; Anuradha Lala, MD^{3,4}; John D. Groarke, MB, MPH⁴; Omar F. AbouEzzeddine, MD⁵; Shannon M. Dunlay, MD, MS⁵; Justin L. Grodin, MD⁶; Victor G. Dávila-Román, MD¹; Lisa de las Fuentes, MD, MS¹

- 1. Washington University School of Medicine, St. Louis, Missouri
- 2. Duke Clinical Research Institute, Durham, North Carolina
- 3. Mount Sinai Hospital, New York, New York
- 4. Brigham and Women's Hospital, Harvard University, Boston, Massachusetts
- 5. Mayo Clinic, Rochester, Minnesota
- 6. Cleveland Clinic, Cleveland, Ohio

Funding: This work was supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (coordinating center: U10 HL084904; regional clinical centers: U01 HL084861, U10 HL110312, U109 HL110337, U01 HL084889, U01 HL084890, U01 HL084891, U10 HL110342, U10 HL110262, U01 HL084931, U10 HL110297, U10 HL110302, U10 HL110309, U10 HL110336, U10 HL110338).

Disclosures: RJM receives research support from the NIH, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Novartis, Otsuka, and ResMed; honoraria from Thoratec; and has served on an advisory board for Luitpold Pharmaceuticals, Inc. DD receives research support from the American Heart Association, Amgen, Maquet, Novartis, and Thoratec. SMD receives funding from the NIH (K23 HL116643)

Correspondence: Justin M. Vader MD, Cardiovascular Division, Washington University in St. Louis. 660 South Euclid Ave, Campus Box 8086 St. Louis, MO 63110. Fax: 314-362-4619. Phone: 314-362-1291. Email: ivader@dom.wustl.edu

Download English Version:

https://daneshyari.com/en/article/5614138

Download Persian Version:

https://daneshyari.com/article/5614138

<u>Daneshyari.com</u>